BIOMAT Database Logo BIOMAT Database Logo

Clinical significance of human hepatocyte growth factor in blood from patients with fulminant hepatic failure. 1989

H Tsubouchi, and S Hirono, and E Gohda, and H Nakayama, and K Takahashi, and O Sakiyama, and H Miyazaki, and J Sugihara, and E Tomita, and Y Muto
Second Department of Internal Medicine, Faculty of Medicine, Kagoshima University, Japan.

We have recently found the presence of human hepatocyte growth factor in sera of patients with fulminant hepatic failure and have purified human hepatocyte growth factor from plasma of a patient with fulminant hepatic failure. In this paper, we report the clinical significance of human hepatocyte growth factor in blood from patients with fulminant hepatic failure. The effect of sera or plasma from 17 patients with fulminant hepatic failure on liver cell growth was examined by use of adult rat hepatocytes in primary cultures. Sera or plasma from 16 of the 17 patients with fulminant hepatic failure stimulated DNA synthesis in hepatocytes more effectively than normal human serum. The mean growth-promoting activity for the 17 patients with fulminant hepatic failure was about 16 times higher than that obtained for normal human serum. This growth-promoting activity of the patients' blood was not related to sex, age, clinical outcome of the patients or type of fulminant hepatic failure, but was intimately related to the clinical grade of hepatic coma. Sera or plasma with Grade III and IV coma showed stimulatory activity on DNA synthesis more markedly than sera or plasma from patients with coma of less than Grade II. In the surviving group, this activity decreased as the hepatic coma of patients improved. In fact, this activity of sera from patients at the recovery stage showed no significant increase compared with that of normal human serum. In the group of terminal patients, this activity increased as the coma developed.(ABSTRACT TRUNCATED AT 250 WORDS)

UI MeSH Term Description Entries
D008099 Liver A large lobed glandular organ in the abdomen of vertebrates that is responsible for detoxification, metabolism, synthesis and storage of various substances. Livers
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D002478 Cells, Cultured Cells propagated in vitro in special media conducive to their growth. Cultured cells are used to study developmental, morphologic, metabolic, physiologic, and genetic processes, among others. Cultured Cells,Cell, Cultured,Cultured Cell
D004247 DNA A deoxyribonucleotide polymer that is the primary genetic material of all cells. Eukaryotic and prokaryotic organisms normally contain DNA in a double-stranded state, yet several important biological processes transiently involve single-stranded regions. DNA, which consists of a polysugar-phosphate backbone possessing projections of purines (adenine and guanine) and pyrimidines (thymine and cytosine), forms a double helix that is held together by hydrogen bonds between these purines and pyrimidines (adenine to thymine and guanine to cytosine). DNA, Double-Stranded,Deoxyribonucleic Acid,ds-DNA,DNA, Double Stranded,Double-Stranded DNA,ds DNA
D005260 Female Females
D006133 Growth Substances Signal molecules that are involved in the control of cell growth and differentiation. Mitogens, Endogenous,Endogenous Mitogens
D006501 Hepatic Encephalopathy A syndrome characterized by central nervous system dysfunction in association with LIVER FAILURE, including portal-systemic shunts. Clinical features include lethargy and CONFUSION (frequently progressing to COMA); ASTERIXIS; NYSTAGMUS, PATHOLOGIC; brisk oculovestibular reflexes; decorticate and decerebrate posturing; MUSCLE SPASTICITY; and bilateral extensor plantar reflexes (see REFLEX, BABINSKI). ELECTROENCEPHALOGRAPHY may demonstrate triphasic waves. (From Adams et al., Principles of Neurology, 6th ed, pp1117-20; Plum & Posner, Diagnosis of Stupor and Coma, 3rd ed, p222-5) Encephalopathy, Hepatic,Portosystemic Encephalopathy,Encephalopathy, Hepatocerebral,Encephalopathy, Portal-Systemic,Encephalopathy, Portosystemic,Fulminant Hepatic Failure with Cerebral Edema,Hepatic Coma,Hepatic Stupor,Hepatocerebral Encephalopathy,Portal-Systemic Encephalopathy,Coma, Hepatic,Comas, Hepatic,Encephalopathies, Hepatic,Encephalopathies, Hepatocerebral,Encephalopathies, Portal-Systemic,Encephalopathies, Portosystemic,Encephalopathy, Portal Systemic,Hepatic Comas,Hepatic Encephalopathies,Hepatic Stupors,Hepatocerebral Encephalopathies,Portal Systemic Encephalopathy,Portal-Systemic Encephalopathies,Portosystemic Encephalopathies,Stupor, Hepatic,Stupors, Hepatic
D006505 Hepatitis INFLAMMATION of the LIVER. Hepatitides
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

H Tsubouchi, and S Hirono, and E Gohda, and H Nakayama, and K Takahashi, and O Sakiyama, and H Miyazaki, and J Sugihara, and E Tomita, and Y Muto
[Existence and clinical significance of human hepatocyte growth factor in sera and plasma from patients with fulminant hepatic failure].
July 1988, Fukuoka igaku zasshi = Hukuoka acta medica,
H Tsubouchi, and S Hirono, and E Gohda, and H Nakayama, and K Takahashi, and O Sakiyama, and H Miyazaki, and J Sugihara, and E Tomita, and Y Muto
Hepatocyte growth factor in fulminant hepatic failure.
February 1990, Hepatology (Baltimore, Md.),
H Tsubouchi, and S Hirono, and E Gohda, and H Nakayama, and K Takahashi, and O Sakiyama, and H Miyazaki, and J Sugihara, and E Tomita, and Y Muto
[Characteristics and partial purification of human hepatocyte growth factor in plasma from patients with fulminant hepatic failure].
November 1988, Fukuoka igaku zasshi = Hukuoka acta medica,
H Tsubouchi, and S Hirono, and E Gohda, and H Nakayama, and K Takahashi, and O Sakiyama, and H Miyazaki, and J Sugihara, and E Tomita, and Y Muto
Significance of serum human hepatocyte growth factor levels in patients with hepatic failure.
January 1992, Hepatology (Baltimore, Md.),
H Tsubouchi, and S Hirono, and E Gohda, and H Nakayama, and K Takahashi, and O Sakiyama, and H Miyazaki, and J Sugihara, and E Tomita, and Y Muto
Biological and immunological properties of human hepatocyte growth factor from plasma of patients with fulminant hepatic failure.
June 1990, Biochimica et biophysica acta,
H Tsubouchi, and S Hirono, and E Gohda, and H Nakayama, and K Takahashi, and O Sakiyama, and H Miyazaki, and J Sugihara, and E Tomita, and Y Muto
Hepatocyte growth factor and plasminogen activation in fulminant hepatic failure.
August 1994, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis,
H Tsubouchi, and S Hirono, and E Gohda, and H Nakayama, and K Takahashi, and O Sakiyama, and H Miyazaki, and J Sugihara, and E Tomita, and Y Muto
[Purification and partial characterization of hepatocyte growth factor from plasma of patients with fulminant hepatic failure].
January 1989, Fukuoka igaku zasshi = Hukuoka acta medica,
H Tsubouchi, and S Hirono, and E Gohda, and H Nakayama, and K Takahashi, and O Sakiyama, and H Miyazaki, and J Sugihara, and E Tomita, and Y Muto
Human fetal hepatocyte transplantation in patients with fulminant hepatic failure.
October 1994, Transplantation,
H Tsubouchi, and S Hirono, and E Gohda, and H Nakayama, and K Takahashi, and O Sakiyama, and H Miyazaki, and J Sugihara, and E Tomita, and Y Muto
Abrogation of Fas-induced fulminant hepatic failure in mice by hepatocyte growth factor.
March 1998, Biochemical and biophysical research communications,
H Tsubouchi, and S Hirono, and E Gohda, and H Nakayama, and K Takahashi, and O Sakiyama, and H Miyazaki, and J Sugihara, and E Tomita, and Y Muto
Hepatic expression of hepatocyte-growth-factor-like/macrophage-stimulating protein mRNA in fulminant hepatic failure.
July 1994, Lancet (London, England),
Copied contents to your clipboard!